Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Insulin-GLP1
- Development stage
- Preclinical
- Lead developer
- Sekkei Bio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
Insulin-GLP1 is a preclinical-stage biologic drug candidate being developed by Sekkei Bio for the treatment of diabetes and obesity. Designed as a dual agonist, the molecule targets both the insulin receptor and the glucagon-like peptide-1 (GLP-1) receptor. This fusion or conjugate approach aims to integrate the potent glucose-lowering effects of insulin with the metabolic benefits of GLP-1 receptor activation, such as enhanced insulin secretion, slowed gastric emptying, and weight reduction. The program is currently in the discovery and preclinical development phase, with no clinical data yet available.
- Other names
- insulin + GLP-1Insulin-GLP1 fusion proteinInsulin-GLP-1 fusion proteinInsulin-GLP 1 fusion protein
02
Targets
GLP1R (GLP-1R)INSR (Insulin receptor)
Beyond the preview
Go deeper on Insulin-GLP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Insulin-GLP1.